ALFA FinderNSE filing, NSE: BETA. Summary written from the filing by ALFA Finder's alert engine.
Beta Drugs Ltd: key numbers
- Share price
- ₹1,878.30
- Market cap
- ₹2,082 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 40.1×Sector 43.8×
- Promoter holding
- 58.91%-0.19% QoQ
- FII holding
- 1.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beta Drugs Ltd
All →Beta Drugs Other Announcement
Beta Drugs filed its sixth monitoring agency report for the quarter ended 30 September 2026. Brickwork Ratings reported no deviation in utilisation of the preferential issue proceeds.
Beta Drugs Other Announcement
Beta Drugs Limited submitted its quarterly Statement of Deviation or Variation for the preferential issue proceeds, confirming no deviation from the stated objects.
Beta Drugs Earnings Call Transcript: Key Takeaways
Management projects a 20-25% growth trajectory despite Q2 bottlenecks. Recent acquisitions and niche oncology focus underpin expansion strategy.
- Call
- Guides 25% growth
Beta Drugs Investor Presentation: Key Takeaways
Beta Drugs reported H1 FY27 revenue of INR 263 Cr with EBITDA margins expanding to 23.2%. The firm is transitioning from a CMO to a branded specialty oncology powerhouse.
Beta Drugs Q2 FY27 Results: Net Profit ₹18.55 Cr, Up 51.8% YoY
Beta Drugs Ltd reported revenue from operations of ₹137.5 Cr (+33.0% YoY) and net profit of ₹18.55 Cr (+51.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.55 Cr · +51.8% YoY
Beta Drugs Board Meeting Date
Beta Drugs Limited notified the exchange of a board meeting scheduled for 22-Oct-2026 to consider quarterly financial results. The trading window closure was also intimated.
Other acquisition announcements
All →Kothari Industrial Corporation Acquisition Worth ₹45 Cr
Kothari Industrial confirmed the PAS-3 filing for its ₹45 crore share acquisition in associate PKFPL. The 4.5 crore shares at ₹10 each complete regulatory formalities.
- Value
- ₹45.00 Cr
eClerx Services Acquisition Worth ₹111.6 Cr
eClerx's subsidiary acquires 100% of RegEdge LLC for up to ₹111.6 Crore. The deal deepens regulatory consulting for financial institutions.
- Value
- ₹111.6 Cr
- Execution
- Expected within 2 weeks subject to closing conditions
GP Petroleums Acquisition Worth ₹44.27 Cr
GP Petroleums signed a share purchase agreement for a 22.45% stake in Incubit Pipavav Terminal, up to Rs.44.27 Crore. Payment is spread over one year in tranches.
- Value
- ₹44.27 Cr
- Execution
- One year, payable in one or more tranches
Cupid Acquisition Worth ₹137.9 Cr
Cupid Limited will acquire Baazar Style Retail Ltd for Rs. 137.87 Crore in cash, paid on exercise of warrant conversion into equity shares. The deal gives Cupid a retail channel to scale its FMCG portfolio.
- Value
- ₹137.9 Cr
- Execution
- As per timelines under SEBI (ICDR) Regulations, 2018
EIH Associated Hotels Acquisition Worth ₹0.46 Cr
EIH Associated Hotels will invest up to 26% in solar SPV Avaada Indsolar for up to Rs 0.46 crore. It secures renewable power for its hotels.
- Value
- ₹0.46 Cr
- Execution
- Completion by March 2027
- solar capacity
- 1.0 MWac
Alivus Life Sciences Acquisition
Alivus Life Sciences signed a Shareholders' Agreement with IQGEN-X Pharma and its continuing shareholders. It governs inter se rights after the company's 76% IQGEN-X stake purchase.